Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPOCAAVI: ICG Angiography for Parathyroid Detection and Hypoparathyroidism Prevention After Total Thyroidectomy
2024-516255-41-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of indocyanine green in thyroid disease, hypoparathyroidism and hypocalcemia, sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Albumin-corrected hypocalcaemia within 48 hours. Planned start Jul 2024; status: authorised.
02
Drugs
indocyanine green
03
Conditions
thyroid diseasehypoparathyroidismhypocalcemia
Beyond the preview
Go deeper on 2024-516255-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516255-41-00.